Meet Our Leaders from Around the Globe
What is a company without vision and leadership? Meet the team who’s vision and leadership has made us one of the fastest-growing CROs on the market. Click on the picture to read more about each leader.
- Jeff WilliamsChief Executive Officer & PresidentJeff WilliamsChief Executive Officer & President
Jeff co-founded Clinipace Worldwide in 2003 with the idea of building a clinical research company that would take a different approach to managing clinical trials. He wanted to build a company where technology served as the foundation of the research. At Clinipace Worldwide, technology is in our DNA with Jeff and his team successfully delivering a technology-amplified approach to conducting research resulting in strong year-over-year growth.
Prior to founding Clinipace Worldwide, Jeff held several executive-level positions within the life sciences and software industries. As CEO of NextAudio, an early pioneer in Internet-based services, he successfully merged the company with Koz to create Mediaspan, a company that expanded to more than 200 employees and earned more than $26 million in sales.
Additionally, Jeff was a co-founder of HealthMatics, one of the first electronic medical records (EMR) software providers, which was sold to A4 Health and later acquired by Allscripts. Prior to these technology endeavors, Jeff spent 10 years at Ciba (now Novartis) and two years at Glaxo Wellcome. During this period, he pioneered some of the earliest direct-to-consumer advertising campaigns within the industry and shared marketing-based responsibility for one of the largest Phase IV studies ever conducted at the time (more than 10,000 patients).
Jeff served on the Board of Directors for CampbellAlliance (prior to its acquisition by InVentiv) and currently serves on the board at Cathedral Corporation, a leader in print and electronic data output services.
Jeff has a Bachelor of Science degree in Chemistry with minors in Business Management and Biology from the University of Tampa.
In 2007, Jeff was named to the PharmaVoice 100, an annual listing of the 100 most influential people in the life sciences industry.
- Ron Marks, PhDChief Scientific OfficerRon Marks, PhDChief Scientific Officer
Ron co-founded Clinipace Worldwide to bring to market an eClinical trial solution that he helped develop at the University of Florida. Ron and his team in the Division of Biostatistics developed a web-based electronic clinical trial system beginning in 1996 that was used to support a 22,000 patient Phase 4 cardiology clinical trial that ran at 870 primary physician sites in 10 countries for 5 years. The University received a patent on multiple aspects of the eClinical system.
Ron was trained as a Biostatistician. He received his MS and PhD in Statistics at the University of Florida and joined the Division of Biostatistics faculty at the J Hillis Miller Health Center at the University of Florida upon graduation. He served on the faculty for 30 years and as Director for 18 years.
Since joining Clinipace Worldwide, Ron serves as Chief Scientific Officer and Global Director of Biostatistics.
- Daryl PorterChief Technology OfficerDaryl PorterChief Technology Officer
Daryl leads the service engineering, product engineering, and cloud computing infrastructure teams.
Prior to Clinipace Worldwide, Daryl spent 18 years at Oracle Corporation and held several executive level positions in both enterprise product development and enterprise support services. Daryl spent most of his career at Oracle in the Database Tools Division as a programmer, manager and vice president where he managed teams ranging from 3 to 300 with commensurate responsibilities around strategic direction, operational execution, budget, and performance.
Daryl concluded his tenure at Oracle as the Vice President of Advanced Support Services. He was responsible for streamlining software life cycle services for global teams of over 10,000 software professionals in five countries and conducting architectural assessments for Fortune 100 Customers in the healthcare, government, financial and telecomm industries to accelerate the adoption of GRID computing and LINUX. He also managed the Oracle-Red Hat relationship as the Oracle OnDemand Service Executive. Additionally, he was an integral member of the M&A technical team tasked with conducting due diligence on Oracle’s acquisitions of Siebel and PeopleSoft.
Daryl holds an Master of Science in Engineering (MSE) in Computer Science from Princeton University, a Bachelor of Science in Mathematical Sciences from the University of North Carolina at Chapel Hill, and is a member of Phi Beta Kappa.
- Andree Beckerling, MD, PhDChief Medical Officer and Chief Executive Officer, EuropeAndree Beckerling, MD, PhDChief Medical Officer and Chief Executive Officer, Europe
Dr. Beckerling is Clinipace’s Chief Medical Officer and European CEO. In these roles, he reports to Jeff Williams, CEO of Clinipace Worldwide, and oversees operations within Europe and medical affairs globally. He joins Clinipace through the merger with the European CRO, Accovion, where he also acted as the Chief Executive Officer and Chief Medical Officer for 5 years. Prior to Clinipace and Accovion, Andree was the Director of Medical Scientific Affairs and Managing Director at Pierrel Research and the Managing Director and Head of Clinical Research at IFE. Andree brings more than 19 years of experience in managing and supervising clinical trials, a profound medical and operational knowledge, as well as a broad business understanding of a highly complex market.
Andree studied Human Medicine at Ruhr-University Bochum Medical School in Bochum, Germany and Boston University Medical Center in Boston, Massachusetts, graduated from Ruhr-University Bochum and finished his post graduate medical education as a Medical Specialist for Pharmaceutical Medicine from the Swiss Association for Pharmaceutical Medicine, Berne, Switzerland. Furthermore, Andree holds an MBA from the University of East London. He’s contributed to multiple medical articles, including Significance of Clinical Research in Germany, Treatment of Depressive Diseases with Sertraline, and Process of Measuring in Clinical Medicine: Implications of Different Definitions in Clinical Therapeutic Studies.
Andree is a member of DGpharMed, DIA, Swiss Association for Pharmaceutical Medicine, Federal Association for Clinical Research in Pediatrics and speaks German and English.
- Hampton CorleyChief Business OfficerHampton CorleyChief Business Officer
As the Chief Business Officer, Hampton is responsible for client advocacy and ensuring client success. With twenty years of business development experience, Hampton’s central goal is to serve clients by aligning Clinipace’s operations team to shepherd the client’s asset and meet their corporate objectives. “We believe our clients need immediate engagement from the appropriate Clinipace regulatory, clinical, or statistical experts to advance to their drug or device development programs. We foster relationships with these value added events”
Hampton built Clinipace Worldwide’s business development organization from the ground up. Nearly 10 years later, Hampton is responsible for the global business development organization which consists of Sales, Proposals and Marketing. Prior to Clinipace, Hampton worked in business development with BioRefrence Laboratories, Ariba, Parametric Technology, and ADP. He graduated with a BBA in Finance from the University of Georgia’s Terry College of Business.
- Ivana WallerChief Business Officer, EuropeIvana WallerChief Business Officer, Europe
Ivana joined Clinipace Worldwide in 2013, through the merger with European CRO, Accovion, where she served as the Chief Operating Officer. Now as Clinipace’s European Chief Business Officer and Managing Director, Ivana is focused largely on client advocacy as well as overseeing the company’s European subsidiaries.
She has been in the clinical research industry for 18 years, serving organizations in both the United States and Europe. Prior to Accovion, Ivana acted as the Vice President of Business Operations at MedTrials for more than a decade.
- Susan Acker-WalshChief Operating OfficerSusan Acker-WalshChief Operating Officer
Susan Acker-Walsh joined the Clinipace team in 2015 and currently serves as the Chief Operating Officer. Susan has a 30 year career in clinical research and offers a powerful blend of entrepreneurial drive, vision, and keen business acumen that has equipped her to launch complex business initiatives and bring them to fruition, create new businesses and develop them into major players in their market space, and adeptly support virtually all functional areas within an organization.
Energized by growth and change, she has served as a “Jill of All Trades,” holding the titles of Chairwoman, CEO, Chief Executive, COO, President, SVP, and VP at various points in her career. Before joining Clinipace in 2015, Susan served as President and COO at SciMetrika, a population health research organization, where she led initiatives focused on planned growth and business execution. Before joining SciMetrika, she spent 13 years with SRA International as VP and Director of Health & Civilian Government. She joined SRA via acquisition where she played an instrumental part in the complex integration of Constella Group into SRA’s new Global Health Sector. She was retained to help lead this effort after serving integral roles on Constella Group’s Executive Leadership Team as SVP of Corporate, Organization and People Development and as the Corporate Compliance Officer. As head of Constella’s Corporate Development function, she initiated and led an acquisition strategy that brought Constella into new global markets, doubled the company’s size overnight, and set EBITDA on track for ninefold growth to $18M.
Susan has an MBA from top-tier Kenan-Flagler Business School at The University of North Carolina at Chapel Hill. She serves as an Adams Advisor at the Center for Entrepreneurial Studies, UNC Kenan-Flagler Business School. She is a William C. Friday Fellow, an Emmy Award–winning film producer, an alumna of Springboard Enterprises, and an active member of the local community, having served on the boards of numerous nonprofit organizations.
- Mike TrudnakChief Security OfficerMike TrudnakChief Security Officer
With more than 22 years of experience, Mike is a seasoned IT executive and strategic thought leader with experience in the software, SaaS (Software-as-a-Service) and clinical research verticals.
Joining Clinipace in 2005, Mike has been a key contributor fueling Clinipace’s growth from a small software startup to an industry-leading global CRO. Mike has performed in a number of technology leadership positions for Clinipace, and he now serves in dual roles as Chief Security Officer and Vice President of Global IT & DataCenter Services.
Partnering with Daryl Porter, Clinipace’s CTO, Mike is responsible for overseeing all aspects of information technology, information security, data and BI analytics across the globe and for supporting the growth of Clinipace's business.
Mike’s proven expertise leading globally distributed teams and rapidly delivering efficient solutions to complex information challenges provides Clinipace a substantial competitive advantage.
- Brian TraversSenior Vice President, Asia PacificBrian TraversSenior Vice President, Asia Pacific
In his current role, Brian leads Clinipace Worldwide’s regional Asia Pacific business. Prior to joining Clinipace Worldwide, Brian served as General Manager, Greater China for inVentiv Health overseeing both the clinical and commercial segments. Before joining inVentiv Health, Brian served as VP – Finance at Pharmalegacy Laboratories, a pre-clinical CRO based in Shanghai, China, where he was responsible for restructuring the organization in order to attract Series B equity investment.
Before Pharmalegacy, he held the dual roles of Senior Manager – Finance & Administration for the International Clinical Diagnostics operations of Thermo Fisher Scientific and Regional Manager - MENA. In these roles he was responsible for overseeing the administrative activities of the operations outside of the US, as well as managing and further developing the distribution business in the Middle East and North Africa. His prior experience also includes financial roles of increasing responsibility for Thermo Fisher Scientific in the US, France, and Germany.
Brian received his Bachelor of Science in Finance and Computer Information Systems from Indiana University – Bloomington, and is currently pursuing a Master of Science in Clinical Research Administration.
- Barb Geiger, BSN, RNEVP, Global OncologyBarb Geiger, BSN, RNEVP, Global Oncology
Barb has more than 25 years of experience in the conduct and management of Phase I-IV clinical trials and project teams. She has global expertise having run trials in more than 30 countries on six continents, and is still waiting for that trial in Antarctica!
Prior to founding Worldwide Clinical Research (WWCR) in 2000, she spent 10 years in leadership roles at global CROs. Additionally, Barb Spent eight years at a major pharmaceutical company and began her career in clinical research in a Phase I/II Private research unit. She is a clinical operations professional and serves our clients as an executive liaison to project teams. An oncology nurse by training, she has extensive experience in oncology and CNS drug development.
- Peter Langecker, MD, PhDExecutive Medical Director, Global OncologyPeter Langecker, MD, PhDExecutive Medical Director, Global Oncology
Peter provides medical expertise within Clinipace and externally, acting as Chief Medical Officer or Medical Monitor for sponsor medical projects and provides clinical development strategy advice, feasibility assessments, and monitoring oversight for select clients. He has more than 25 years of experience in clinical oncology and oncology drug development, specializing in the planning and implementation of clinical Phase I-IV studies, regulatory strategy, and FDA and EMA interactions and submissions. Following his early career as Medical Monitor at Ciba-Geigy and Schering-Plough, he has served in senior roles in several pharmaceutical and biotechnology companies including Coutler, SUGEN, Intarcia, DURECT, and OXiGENE.
Peter received his MD and PhD in medical sciences from the Ludwig-Maximilians University.
- Eric B. Grossman, MDVice President and Medical Director, Global NephrologyEric B. Grossman, MDVice President and Medical Director, Global Nephrology
Eric B. Grossman, MD, is Vice President and Medical Director of Clinipace Worldwide. An eminent nephrologist with over 30 years of industry and clinical experience, Dr. Grossman brings almost two decades of experience designing and conducting clinical studies for FDA submission and top-tier journal publication. In addition to his work in nephrology, Dr. Grossman has conducted studies across a broad range of therapeutic areas including cardiovascular, diabetes, urology, women’s health and oncology. He is Board Certified in Internal Medicine and Nephrology. Prior to joining Clinipace in April 2017, Dr. Grossman was most recently a consultant to the pharmaceutical industry with Bexon Clinical Consulting. Before that, he held positions with Reata Pharmaceuticals, Keryx Biopharmaceuticals, the New York Organ Donor Network and Pfizer. Dr. Grossman received an MD from the University of Chicago Pritzker School of Medicine. He completed his residency at the Tufts-New England Medical Center and his nephrology fellowship at Harvard Medical School’s Brigham and Women’s Hospital in Boston.
- Beth Garrard, PharmDEVP, Global Safety OperationsBeth Garrard, PharmDEVP, Global Safety Operations
A pharmacist by training, Beth has more than 20 years of experience in pharmaceutical product safety based on monitoring adverse event data for use in medical practice for both clinical investigations and post marketing. Her experience includes extensive industry-based global pharmacovigilance with both CROs and sponsor based companies with a focus in clinical research, disease management, quality, regulatory, compliance, training, risk management, benefit risk analysis, aggregate data analysis, and signal detection and management.
Beth completed her doctorate in pharmacy at UNC’s School of Pharmacy in Chapel Hill, NC.
- Nikolas BurlewExec. VP, Regulatory & Strategic Development (RSD) Global ConsultingNikolas BurlewExec. VP, Regulatory & Strategic Development (RSD) Global Consulting
Nik is a Drug Development professional with more than 25 years of experience in the research, development, manufacturing and quality of drugs and biologics. As the Executive Vice President and Head of Operations of RSD Global Consulting, Nik continues to support the development of therapeutics across a wide variety of dosage forms for clinical and commercial use.
Nik says: “The most important consideration a client should take when choosing a development partner is ensuring that they have a clear appreciation of the client’s goals and objectives for their program. Aligning the development efforts at every stage with those goals is the surest way to success.”
- Mark Shapiro, MA, MBAVP, Clinical DevelopmentMark Shapiro, MA, MBAVP, Clinical Development
A pharmacologist by training, Mark has almost 20 years of experience spanning virtually all aspects of drug development.
He completed an MBA at Duke University’s Fuqua School of Business. Prior to Duke, Mark did master’s and doctoral work in pharmacology and biomolecular pharmacology at the Boston University School of Medicine. He received a bachelor’s degree in chemistry at Virginia Tech.
- Cindy Venendaal, PhDVP, Clinical Operations, AmericasCindy Venendaal, PhDVP, Clinical Operations, Americas
Cindy has worked in clinical operations and drug/device development across pharmaceutical, biotechnology, and clinical research organizations for the past 17 years. Her experience includes executing global clinical trials throughout North America, Asia Pacific, Latin America, and Europe. Cindy has managed Phase I-IV clinical trials across a wide variety of therapeutic areas, focusing mainly on oncology studies. She has been heavily involved in vendor selection/management, protocol development, CSR review, and support for IND and NDA submissions/approvals.
Cindy earned her PhD in clinical science from the University of Colorado and Master of Public Health degree from the University of Northern Colorado.
- Martin CrippsVP, Clinical Operations, EuropeMartin CrippsVP, Clinical Operations, Europe
Martin has worked in clinical operations and drug and device development in pharmaceutical, biotechnology, and clinical research organizations for the past 17 years. He has a thorough command of operational requirements in North America, Europe, Asia Pacific, and Africa, and has managed cross-functional and multi-cultural teams ensuring productivity and quality.
- Ingrid Lo, MSVP, Clinical Operations, APACIngrid Lo, MSVP, Clinical Operations, APAC
With more than 14 years of experience in clinical research at the Center of Drug Evaluation, GlaxoSmithKline, Quintiles, and Clinipace, Ingrid has acquired an in-depth knowledge of the drug development, clinical trial conduction, trial management, and regulatory perspectives. She also has experience in managing clinical operations across Phase I to Phase IV in various therapeutic areas, most extensively in vaccine development and oncology.
Ingrid is a licensed pharmacist by training with a bachelor’s degree in pharmacy and a master’s in pharmacology.
- Marie HanleyVP, Global Quality ServicesMarie HanleyVP, Global Quality Services
Marie has worked in the clinical research industry for more than 30 years. Over the past 12 years, she has been in global regulatory and quality assurance roles. With a Bachelor of Science in Nursing and post-graduate work in biostatistics, she began her research career as a research nurse and study coordinator.
Marie is a champion of compliance and process improvement, with global regulatory inspection and audit expertise.
Marie says: "As Steven Covey once said, 'begin with the end in mind.' The end in mind for CPWW and our Sponsors is regulatory approval for a new therapy. Although we maintain a robust internal QA audit program, you can’t audit quality in, it must be a part of the fabric of an organization from the top down and the bottom up. At Clinipace, this perspective is a key to running successful, compliant studies that pass inspections. Having this perspective allows us to challenge the way things have been done, to look for opportunities to improve, and to build reproducible quality into everything we do. This is not a static or singular process, but requires a culture of continual process improvement, staff training, and maintaining a quality system that helps deliver on that objective. Having an awareness, that your ultimate ‘customer’ is the Regulatory Inspector inspecting the study data, the patients who participate, our sites and our Sponsors, keeps our focus on what is important in the conduct of clinical research.“
- Kelli MillerVP, Global Human ResourcesKelli MillerVP, Global Human Resources
Kelli joined Clinipace in 2010. As Vice President, Global Human Resources, she is responsible for developing and executing the human resources strategy in support of the overall business plan and strategic direction of the company. Her primary focus is to align global HR initiatives and resources to meet the needs of Clinipace’s customers, employees, and the executive management team.
Kelli began her career in finance, and has more than 25 years of experience in finance and human resources. Kelli received her Professional in Human Resources (PHR) certification in 2013. She earned her Bachelors of Science in Accounting from Purdue University.